loading page

A prospective study of the efficacy of oral propranolol in reduction of the frequency and severity of epistaxis in Hereditary Haemorrhagic Telangiectasia
  • +3
  • Grigg C,
  • Abigail Walker,
  • Anders Cervin,
  • Girling K,
  • Liu Z,
  • Earnshaw J
Grigg C
Royal Brisbane and Women's Hospital
Author Profile
Abigail Walker
Royal Brisbane and Women's Hospital

Corresponding Author:[email protected]

Author Profile
Anders Cervin
Royal Brisbane and Women's Hospital
Author Profile
Girling K
Royal Brisbane and Women's Hospital
Author Profile
Liu Z
Royal Brisbane and Women's Hospital
Author Profile
Earnshaw J
Royal Brisbane and Women's Hospital
Author Profile

Abstract

1) This pilot trial demonstrated utility of oral propranolol in management of epistaxis in HHT 2) Propranolol was effective in reducing the severity and frequency of nosebleeds in HHT, as measured by the epistaxis severity scale, and this improvement is mirrored by an improvement in global quality of life 3) Adverse effects were experienced by a minority of patients, with the most significant event being pitting oedema 4) Following cessation of treatment, patients demonstrated a trend of regression with worsening of epistaxis scores 5) Further investigation is justified by its favourable effects, wide availability, and minimal side effect profile
09 Nov 2023Submitted to Clinical Otolaryngology
31 Jul 2024Submission Checks Completed
31 Jul 2024Assigned to Editor
04 Aug 2024Reviewer(s) Assigned
08 Sep 2024Review(s) Completed, Editorial Evaluation Pending
09 Sep 2024Editorial Decision: Revise Major